

To
Mr. Ioannis Tountas
President of EOF

Cc: Mr. Andreas Lykourantzou, Minister of Health
Mr. M. Salmas, Deputy Minister of Health
Ms. M. Skouroliaou, Vice-President of EOF
Mr. P. Vassilakis, Vice-President of EOF

Halandri, 23 July 2012

Dear Mr Tountas,

Over the past three years, pharmaceutical companies have sustained a barrage of measures; the haircut of Greek government bonds in their hands, public debts to pharmaceutical companies (€1.65 billion), rebate, decrease of the prices of pharmaceutical products among the lowest in the EU, etc.

Meanwhile, the last three years, since 2009, **pharmaceutical expenditure gradually declines by 45%**, with of course a commensurate impact on the entire pharmaceutical industry.

In this exceptionally negative climate, pharmaceutical companies have the obligation to pay high administrative fees to EOF, while the services provided by EOF are not proportional.

A comparison between the fees paid to EOF and those paid to respective national organisations in other EU countries, including countries with higher GDP, indicates that pharmaceutical companies in Greece pay much higher fees for the same procedures.

EOF fees are among the highest in the EU, whereas they should instead be similar to those levied in EU countries with comparable GDP and market size, such as Portugal, the Czech Republic and Slovenia.

Taking into consideration the extremely difficult situation for our country and pharmaceutical enterprises, it is of the outmost importance to rationalize the height of administrative fees and **reduce them from September 1st by 35%**.

Sincerely,

Ioannis Vlonztos
Vice-President

Konstantinos M. Frouzis
President